COMP <GO>
TAK vs JNJ // FORWARD P/E MULTIPLE
Takeda Pharmaceutical Company Limited American (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TAK 2
— JNJ 12
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $20.91 (+4.50%) • MKT CAP: $63.23B
forward-pe
30.5x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TAK VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TAK | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 25.50% | -15.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 18.5x | +2.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 2.97% | -0.76 | JNJ | /fcf-yield <GO> |
| Operating Margin | 13.90% | 34.70% | -20.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 28.50% | -17.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 6.00% | -9.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 5.59 | -1.85 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | TAK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.9 | 60.4 | +11.52 | TAK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.08 | -0.02 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 30.5x | 23.0x | +7.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.23B | $662.49B | -$599.26B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TAK REV | JNJ REV | TAK GROSS % | JNJ GROSS % | TAK FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $94.19B | — | 67.9% | — | $19.70B |
| FY 2024 | — | $88.82B | — | 69.1% | — | $19.84B |
| FY 2023 | — | $85.16B | — | 44.0% | — | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TAK // BETA 1.06
JNJ // BETA 1.08